A possible mechanism of antibody-dependent cellular cytotoxicity (ADCC) of lymphokine-activated killer cells (LAK) with cetuximab for the treatment of mutated KRAS or BRAF metastatic colorectal cancer (mCRC).
Y. Inoue
No relevant relationships to disclose
S. Hazama
No relevant relationships to disclose
M. Irie
No relevant relationships to disclose
Y. Shindo
No relevant relationships to disclose
Y. Maeda
No relevant relationships to disclose
N. Suzuki
No relevant relationships to disclose
K. Yoshimura
No relevant relationships to disclose
S. Yoshino
No relevant relationships to disclose
M. Oka
No relevant relationships to disclose